Your search history is turned on.
Date: March 6, 2024 Jurisdictions: Ontario
Microsoft Word - Acerus Pharmaceuticals Corporation - Final Decision Document (Conformed signature) 20230920 Ontario Commission des 22nd Floor 22e tage Securities valeurs mobilires 20 Queen Street West 20, rue queen oust Commission de lOntario Toronto ON M5H 3S8 Toronto ON M5H 3S8 IN THE MATTER OF THE BUSINESS CORPORATIONS ACT (ONTARIO), R.S.O. 1990, c. B...
Date: January 26, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Acerus - CCAA PR FINAL.docx 116705084 v2 ACERUS FILES FOR CCAA PROTECTION TORONTO, JANUARY 26, 2023 Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collect...
Date: December 28, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Acerus - Resignation of Director (12-26-22).docx 1 ACERUS ANNOUNCES RESIGNATION OF DIRECTOR TORONTO, December 26, 2022 Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately. ...
Date: December 22, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Acerus - FGC_New Loan PR (Final 12-21-22).docx 1 116583482 v2 ACERUS ANNOUNCES NEW LOAN AGREEMENT WITH FIRST GENERATION CAPITAL TORONTO, December 22, 2022 Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX: ASP; OTCQB: ASPCF) today announced that it and its wholly-owned subsidiary, Acerus Pharmaceuticals US...
Date: November 14, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Form 52-109F2 (CFO Q3 2022).docx FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Robert Motz, Chief Financial Officer of Acerus Pharmaceuticals Corporation, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Acerus Pharmaceuticals Corpor...
Microsoft Word - Form 52-109F2 (CEO Q3 2022).docx FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Edward Gudaitis, President and Chief Executive Officer, of Acerus Pharmaceuticals Corporation, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Acerus Ph...
SETOR1-#5884973-v2-Trimel_Q3_2011_MD&A.DOC 1 Managements Discussion & Analysis of Acerus Pharmaceuticals Corporation For the three and nine months ended September 30, 2022 The following managements discussion and analysis (MD&A) of the financial condition and results of the operations of Acerus Pharmaceuticals ...
Acerus Pharmaceuticals Corporation Unaudited Condensed Interim Consolidated Financial Statements September 30, 2022 (expressed in thousands of U.S. dollars except per share amounts and unless otherwise stated) Acerus Pharmaceuticals Corporation Condensed Interim Consolidated Statements of Financial Position As at September 30, 2022 and December 31, 2021 Un...
Date: October 3, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Acerus -Serenity - Press Release September 30 2022_Final.docx 1 ACERUS ANNOUNCES AMENDMENT TO PROMISSORY NOTE DUE TO FORMER SERENITY SHAREHOLDERS Toronto, Canada, October 3, 2022 Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the N...
Date: September 21, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Acerus Announces Strategic Review_v2_09202022_.docx 1 ACERUS ANNOUNCES INITIATION OF STRATEGIC REVIEW Ernst & Young Orenda Corporate Finance Inc. (EY) engaged as independent financial advisors Toronto, Canada: September 21, 2022: Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX: ASP; OTCQB: ASPCF) toda...